PriceTargets.com logo

Annovis Bio - ANVS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.17
  • Forecasted Upside: 636.08%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$4.37 As of 12/20/2024 06:31 PM ET
▼ -0.03 (-0.68%)

This chart shows the closing price for ANVS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Annovis Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANVS

Analyst Price Target is $32.17
▲ +636.08% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Annovis Bio in the last 3 months. The average price target is $32.17, with a high forecast of $67.00 and a low forecast of $9.00. The average price target represents a 636.08% upside from the last price of $4.37.

This chart shows the closing price for ANVS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Annovis Bio. This rating has held steady since July 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
10/25/2024Maxim GroupUpgradeHold ➝ Buy$25.00
10/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
10/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
8/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
8/13/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
7/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
7/11/2024HC WainwrightBoost TargetBuy ➝ Buy$23.00 ➝ $30.00
7/2/2024Rodman & RenshawReiterated RatingBuy ➝ Buy$67.00 ➝ $67.00
6/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
6/4/2024Rodman & RenshawInitiated CoverageBuy$67.00
5/13/2024HC WainwrightLower TargetBuy ➝ Buy$30.00 ➝ $23.00
4/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00
4/30/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$36.00 ➝ $26.00
4/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00
3/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00
2/28/2024Brookline Capital ManagementDowngradeBuy ➝ Hold$9.00
12/29/2023Canaccord Genuity GroupInitiated CoverageBuy$36.00
12/29/2023Canaccord Genuity GroupInitiated CoverageBuy$36.00
11/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$30.00
11/13/2023HC WainwrightLower TargetBuy ➝ Buy$40.00 ➝ $30.00
11/10/2023Brookline Capital ManagementReiterated RatingBuy$35.00
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$40.00
4/21/2023HC WainwrightReiterated RatingBuy$40.00
2/8/2023HC WainwrightReiterated RatingBuy$40.00
9/8/2022HC WainwrightInitiated CoverageBuy$40.00
5/2/2022LADENBURG THALM/SH SHInitiated CoverageBuy
10/8/2021Maxim GroupInitiated CoverageBuy$70.00
7/7/2021Maxim GroupBoost TargetBuy$45.00 ➝ $150.00
5/21/2021Maxim GroupInitiated CoverageBuy$45.00
5/13/2021Maxim GroupBoost TargetBuy$12.00 ➝ $45.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 25 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 4 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 3 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 5 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Annovis Bio logo
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
Read More

Today's Range

Now: $4.37
Low: $4.30
High: $4.53

50 Day Range

MA: $7.32
Low: $4.37
High: $9.88

52 Week Range

Now: $4.37
Low: $4.30
High: $22.49

Volume

329,981 shs

Average Volume

718,486 shs

Market Capitalization

$60.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Annovis Bio?

The following Wall Street analysts have issued research reports on Annovis Bio in the last year: Brookline Capital Management, Canaccord Genuity Group Inc., EF Hutton Acquisition Co. I, HC Wainwright, Maxim Group, and Rodman & Renshaw.
View the latest analyst ratings for ANVS.

What is the current price target for Annovis Bio?

0 Wall Street analysts have set twelve-month price targets for Annovis Bio in the last year. Their average twelve-month price target is $32.17, suggesting a possible upside of 636.1%. Rodman & Renshaw has the highest price target set, predicting ANVS will reach $67.00 in the next twelve months. Brookline Capital Management has the lowest price target set, forecasting a price of $9.00 for Annovis Bio in the next year.
View the latest price targets for ANVS.

What is the current consensus analyst rating for Annovis Bio?

Annovis Bio currently has 1 hold rating, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ANVS will outperform the market and that investors should add to their positions of Annovis Bio.
View the latest ratings for ANVS.

What other companies compete with Annovis Bio?

Other companies that are similar to Annovis Bio include Benitec Biopharma, Foghorn Therapeutics, Eledon Pharmaceuticals, UroGen Pharma and Rezolute. Learn More about companies similar to Annovis Bio.

How do I contact Annovis Bio's investor relations team?

Annovis Bio's physical mailing address is 1055 Westlakes Drive Suite 300, Berwyn PA, 19312. The company's listed phone number is 610-727-3913 and its investor relations email address is [email protected]. The official website for Annovis Bio is www.annovisbio.com. Learn More about contacing Annovis Bio investor relations.